These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 24768216)

  • 1. Rituximab use in pediatric central demyelinating disease.
    Beres SJ; Graves J; Waubant E
    Pediatr Neurol; 2014 Jul; 51(1):114-8. PubMed ID: 24768216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuromyelitis optica in children. Two case reports].
    Tosello B; Halbert C; Mancini J; Chabrol B; Boucraut J; Milh M
    Arch Pediatr; 2012 Aug; 19(8):827-31. PubMed ID: 22789744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rituximab in pediatric neuromyelitis optica.
    Mahmood NA; Silver K; Onel K; Ko M; Javed A
    J Child Neurol; 2011 Feb; 26(2):244-7. PubMed ID: 21183724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
    Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
    J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
    Bedi GS; Brown AD; Delgado SR; Usmani N; Lam BL; Sheremata WA
    Mult Scler; 2011 Oct; 17(10):1225-30. PubMed ID: 21622594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of rituximab treatment for neuromyelitis optica.
    Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
    Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of cases of neuromyelitis optica.
    Bomprezzi R; Postevka E; Campagnolo D; Vollmer TL
    Neurologist; 2011 Mar; 17(2):98-104. PubMed ID: 21364364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
    Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
    Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
    Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
    Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
    JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system].
    Yang Y; Wu WP; Huang DH; Wu L
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(43):3032-5. PubMed ID: 23328372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuromyelitis optica].
    Kvistad SA; Wergeland S; Torkildsen Ø; Myhr KM; Vedeler CA
    Tidsskr Nor Laegeforen; 2013 Oct; 133(19):2057-61. PubMed ID: 24129537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report.
    Lee DH; Laemmer AB; Waschbisch A; Struffert T; Maihöfner C; Schwab S; Linker RA
    J Med Case Rep; 2014 May; 8():155. PubMed ID: 24886528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis optica.
    Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
    Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
    Pellkofer HL; Krumbholz M; Berthele A; Hemmer B; Gerdes LA; Havla J; Bittner R; Canis M; Meinl E; Hohlfeld R; Kuempfel T
    Neurology; 2011 Apr; 76(15):1310-5. PubMed ID: 21482945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
    Ringelstein M; Harmel J; Distelmaier F; Ingwersen J; Menge T; Hellwig K; Kieseier B; Mayatepek E; Hartung HP; Kuempfel T; Aktas O
    Mult Scler; 2013 Oct; 19(11):1544-7. PubMed ID: 23886825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.